DPCO price of TD Vaccine and Tacrolimus Tablet

Spread the love

DPCO price of TD Vaccine and Tacrolimus Tablet
dpco-td-vaccine

NPPA has fixed the ceiling prices of 6 formulations under Drugs (Prices Control) Order, 2013 relating to the 80th Authority meeting dated 26.10.2020. 6 formulations are different dosage and packing of TD Vaccine and Tacrolimus tablet 0.5mg, 1mg, and 2mg strength. The detailed tablet is contained strength, Retail ceiling price, and unit in the DPCO price of TD Vaccine and Tacrolimus Tablet.

New Delhi, 3rd November 2020

ORDER


S. O. 3973(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Also read: Best cough syrups name in India 2020

DPCO price of TD Vaccine and Tacrolimus Tablet

Sl. No.
NAME OF THE
SCHEDULED FORMULATION
DOSAGE FORM & STRENGTHUNITCEILING
PRICE (RS.)
1TD Vaccine

Each dose of 0.5ml contains:
Diphtheria Toxoid ≤5Lf (≥ 2IU)
Tetanus Toxoid ≥ 5Lf (≥ 40IU)
Each 0.5ml
Pack
18.69
2TD Vaccine

Each dose of 0.5ml contains:
Diphtheria Toxoid ≤5Lf (≥ 2IU)
Tetanus Toxoid ≥ 5Lf (≥ 40IU)
Each 5ml
Pack
175.59
3TD Vaccine Each dose of 0.5ml contains:
Diphtheria Toxoid ≤25Lf (≥ 30IU)
Tetanus Toxoid ≥ 5Lf (≥ 40IU)
Each 0.5ml
Pack
16.02
4Tacrolimus Tablet Tacrolimus 0.5 mg1 Tablet18.68
5Tacrolimus TabletTacrolimus 1 mg1 Tablet34.31
6Tacrolimus Tablet Tacrolimus 2 mg1 Tablet67.77
table

Note:
(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling
price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling
the price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish a quarterly return to the NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit
the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.


PN/212/80/2020/F F. No. 8(80)/2020/D.P./NPPA-Div.-II

Related Posts :

Visit for Third Party Manufacturing for all dosage form WhatsApp your querry on below link:


Spread the love